|
Firm |
Analyst |
| Dawson James | Jason Kolbert |
|
H.C. Wainwright & Co. |
Raghuram Selvaraju, Ph.D. |
|
Jacques A. Villefranc, Ph.D. |
|
| Maxim Group |
Caroline Palomeque |
| National Securities |
Jonathan Aschoff, Ph.D. |
|
Oppenheimer & Co., Inc. |
Leland Gershell, MD, Ph.D. |
|
Roth Capital Partners |
Jerry Isaacson, Ph.D. |
|
Trickle Research |
David Lavigne |
|
Zacks |
John D. Vandermosten |
|
AzurRx BioPharma, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding AzurRx BioPharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of AzurRx BioPharma, Inc. or its management. AzurRx BioPharma, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
|
